In Response to "De Novo KRAS G12C-Mutant SCLC: A Case Report"

Margaret Moore¹, Yuyang Zhuo¹, Jeffrey D Mandell², Stephen G Gaffney¹, Jeffrey P Townsend^{1

2

3}

Affiliations

¹ Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
² Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut.
³ Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut.

Margaret Moore et al. JTO Clin Res Rep. 2022.

. 2022 Sep 27;3(12):100418.

doi: 10.1016/j.jtocrr.2022.100418. eCollection 2022 Dec.

Margaret Moore¹, Yuyang Zhuo¹, Jeffrey D Mandell², Stephen G Gaffney¹, Jeffrey P Townsend^{1

2

3}

¹ Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
² Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut.
³ Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut.

No abstract available

References

1. Balbach M.L., Eisenberg R., Iams W.T. De novo KRAS G12C–mutant SCLC: a case report. JTO Clin Res Rep. 2022;3 - PMC - PubMed
1. Cannataro V.L., Gaffney S.G., Townsend J.P. Effect sizes of somatic mutations in cancer. J Natl Cancer Inst. 2018;110:1171–1177. - PMC - PubMed
1. Zhuo Y. YuyangZhuo/SCLC_cancereffectsizeR: SCLC_cancereffectsizeR. https://zenodo.org/record/7010662#.YzLUPnZBy3A - DOI
1. Wang H., Liu B., Wei J. Beta 2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy. Cancer Lett. 2021;517:96–104. - PubMed
1. Zhao Y., Cao Y., Chen Y., et al. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Immunology. 2021;164:507–523. - PMC - PubMed